Viridian prices USD 225 million 1.75% convertible senior notes due 2032

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

VRDN

0.00
  • Viridian priced USD 225 million of 1.75% convertible senior notes due 2032 in an upsized public offering.
  • Net proceeds from debt offering, combined with concurrent equity sale, expected at about USD 334.7 million.
  • Interest payable semiannually starting Nov. 15, 2026; notes mature May 15, 2032.
  • Initial conversion rate set at 40.5680 shares per USD 1,000 principal, implying an initial conversion price of about USD 24.65.
  • Proceeds earmarked to repay Hercules Capital debt, support thyroid eye disease expansion studies, advance earlier pipeline, fund general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.